Compounds for the treatment of metabolic disorders

A compound of the formula:

• wherein
• n is 1 or 2;
• m is 0 or 1;
• q is 0 or 1;
• t is 0 or 1;
• R5 is alkyl having from 1 to 3 carbon atoms;
• and
• R9 is hydrogen;
• and
• X is —CH2CR12R13— wherein one of R12 and R13 is hydrogen or methyl and the other is methyl, Q is OR1 and R1 is hydrogen or alkyl having from 1 to 7 carbon atoms;
• or X is —CH2CH2— and Q is NR10R11 wherein one of R10 and R11 is hydrogen, alkyl having from 1 to 3 carbon atoms or hydroxy, and the other is hydrogen or alkyl having from 1 to 3 carbon atoms;
• or
• R9 is halo, or alkoxy having from 1 to 3 carbon atoms;
• and
• X is —CH2—, Q is —OR1 and R1 is ethyl;
• or X is —CH2CR12R13— or —CH2CH(NHAc)— wherein each of R12 and R13 is independently hydrogen or methyl, Q is OR1 and R1 is hydrogen or alkyl having from 1 to 7 carbon atoms;
• or X is —CH2CH2— and Q is NR10R11 wherein one of R10 and R11 is hydrogen, alkyl having from 1 to 3 carbon atoms or hydroxy, and the other is hydrogen or alkyl having from 1 to 3 carbon atoms;
• and
• A is a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I′ by a ring carbon;
• or when R1 is hydrogen, a pharmaceutically acceptable salt of the compound.